Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
The Cerebellum
Erschienen in:

01.06.2019 | Original Paper

Differential Expression of Genes for Ubiquitin Ligases in Medulloblastoma Subtypes

verfasst von: Jerry Vriend, Robert B. Tate

Erschienen in: The Cerebellum | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Using publically available datasets on gene expression in medulloblastoma (MB) subtypes, we selected genes for ubiquitin ligases and identified statistically those that best predicted each of the four major MB subgroups as separate disease entities. We identify a gene coding for an ubiquitin ligase, ZNRF3, whose overexpression alone can predict the WNT subgroup for 100% in the Pfister dataset. For the SHH subgroup, we identify a gene for a regulatory subunit of the protein phosphatase 2A (PP2A), PPP2R2C, as the major predictor among the E3 ligases genes. The ubiquitin and ubiquitin-like conjugation database (UUCD) lists PPP2R2C as coding for a Cullin Ring ubiquitin ligase adaptor. For group 3 MBs, the best ubiquitin ligase predictor was PPP2R2B, a gene which codes for another regulatory subunit of the PP2A holoenzyme. For group 4, the best E3 gene predictors were MID2, ZBTB18, and PPP2R2A, which codes for a third PP2A regulatory subunit. Heatmap analysis of the E3 gene data shows that expression of ten genes for ubiquitin ligases can be used to classify MBs into the four major consensus subgroups. This was illustrated by analysis of gene expression of ubiquitin ligases of the Pfister dataset and confirmed in the dataset of Cavalli. We conclude that genes for ubiquitin ligases can be used as genetic markers for MB subtypes and that the proteins coded for by these genes should be investigated as subtype specific therapeutic targets for MB.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2012;123(4):465–72.CrossRefPubMed
2.
Kool M, Korshunov A, Remke M, Jones DT, Schlanstein M, Northcott PA, et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, group 3, and group 4 medulloblastomas. Acta Neuropathol. 2012;123(4):473–84.CrossRefPubMedPubMedCentral
3.
Koo BK, Spit M, Jordens I, Low TY, Stange DE, van de Wetering M, et al. Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. Nature. 2012;488(7413):665–9.CrossRefPubMed
4.
Hsia EY, Gui Y, Zheng X. Regulation of hedgehog signaling by ubiquitination. Front Biol (Beijing). 2015;10(3):203–20.CrossRef
5.
6.
Hammond-Martel I, Yu H, el Affar B. Roles of ubiquitin signaling in transcription regulation. Cell Signal. 2012;24(2):410–21.CrossRefPubMed
7.
8.
DeSouza RM, Jones BR, Lowis SP, Kurian KM. Pediatric medulloblastoma - update on molecular classification driving targeted therapies. Front Oncol. 2014;4:176.CrossRefPubMedPubMedCentral
9.
Bielskiene K, Bagdoniene L, Mozuraitiene J, Kazbariene B, Janulionis E. E3 ubiquitin ligases as drug targets and prognostic biomarkers in melanoma. Medicina (Kaunas). 2015;51(1):1–9.CrossRef
10.
Clifford SC, Lusher ME, Lindsey JC, Langdon JA, Gilbertson RJ, Straughton D, et al. Wnt/wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle. 2006;5(22):2666–70.CrossRefPubMed
11.
Thom CS, Traxler EA, Khandros E, Nickas JM, Zhou OY, Lazarus JE, et al. Trim58 degrades dynein and regulates terminal erythropoiesis. Dev Cell. 2014;30(6):688–700.CrossRefPubMedPubMedCentral
12.
Bedford L, Lowe J, Dick LR, Mayer RJ, Brownell JE. Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat Rev Drug Discov. 2011;10(1):29–46.CrossRefPubMed
13.
Shen M, Schmitt S, Buac D, Dou QP. Targeting the ubiquitin-proteasome system for cancer therapy. Expert Opin Ther Targets. 2013;17(9):1091–108.CrossRefPubMedPubMedCentral
14.
Wang L, Wu J, Yuan J, Zhu X, Wu H, Li M. Midline2 is overexpressed and a prognostic indicator in human breast cancer and promotes breast cancer cell proliferation in vitro and in vivo. Front Med. 2016;10(1):41–51.CrossRefPubMed
15.
Mayer RE, Hendrix P, Cron P, Matthies R, Stone SR, Goris J, et al. Structure of the 55-kDa regulatory subunit of protein phosphatase 2A: evidence for a neuronal-specific isoform. Biochemistry. 1991;30(15):3589–97.CrossRefPubMed
16.
17.
18.
19.
20.
21.
22.
23.
Mishra SK, Funair L, Cressley A, Gittes GK, Burns RC. High-affinity Dkk1 receptor Kremen1 is internalized by clathrin-mediated endocytosis. PLoS One. 2012;7(12):e52190.CrossRefPubMedPubMedCentral
24.
Malinauskas T, Aricescu AR, Lu W, Siebold C, Jones EY. Modular mechanism of Wnt signaling inhibition by Wnt inhibitory factor 1. Nat Struct Mol Biol. 2011;18(8):886–93.CrossRefPubMedPubMedCentral
25.
Surmann-Schmitt C, Widmann N, Dietz U, Saeger B, Eitzinger N, Nakamura Y, et al. Wif-1 is expressed at cartilage-mesenchyme interfaces and impedes Wnt3a-mediated inhibition of chondrogenesis. J Cell Sci. 2009;122(Pt 20):3627–37.CrossRefPubMed
26.
Mazieres J, He B, You L, Xu Z, Lee AY, Mikami I, et al. Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res. 2004;64(14):4717–20.CrossRefPubMed
27.
Callow MG, Tran H, Phu L, Lau T, Lee J, Sandoval WN, et al. Ubiquitin ligase RNF146 regulates tankyrase and Axin to promote Wnt signaling. PLoS One. 2011;6(7):e22595.CrossRefPubMedPubMedCentral
28.
Jho EH, Zhang T, Domon C, Joo CK, Freund JN, Costantini F. Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol. 2002;22(4):1172–83.CrossRefPubMedPubMedCentral
29.
Northcott PA, Buchhalter I, Morrissy AS, Hovestadt V, Weischenfeldt J, Ehrenberger T, et al. The whole-genome landscape of medulloblastoma subtypes. Nature. 2017;547(7663):311–7.CrossRefPubMedPubMedCentral
30.
31.
Chen G, Courey AJ. Groucho/TLE family proteins and transcriptional repression. Gene. 2000;249(1–2):1–16.CrossRefPubMed
32.
Coon TA, Glasser JR, Mallampalli RK, Chen BB. Novel E3 ligase component FBXL7 ubiquitinates and degrades Aurora A, causing mitotic arrest. Cell Cycle. 2012;11(4):721–9.CrossRefPubMedPubMedCentral
33.
Liu Y, Lear T, Zhao Y, Zhao J, Zou C, Chen BB, et al. F-box protein Fbxl18 mediates polyubiquitylation and proteasomal degradation of the pro-apoptotic SCF subunit Fbxl7. Cell Death Dis. 2015;6:e1630.CrossRefPubMedPubMedCentral
34.
Liu Y, Lear T, Iannone O, Shiva S, Corey C, Rajbhandari S, et al. The proapoptotic F-box protein Fbxl7 regulates mitochondrial function by mediating the ubiquitylation and proteasomal degradation of survivin. J Biol Chem. 2015;290(19):11843–52.CrossRefPubMedPubMedCentral
35.
Wheatley SP, McNeish IA. Survivin: a protein with dual roles in mitosis and apoptosis. Int Rev Cytol. 2005;247:35–88.CrossRefPubMed
36.
Kamran M, Long ZJ, Xu D, Lv SS, Liu B, Wang CL, et al. Aurora kinase a regulates survivin stability through targeting FBXL7 in gastric cancer drug resistance and prognosis. Oncogene. 2017;6(2):e298.CrossRef
37.
38.
Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, van Sluis P, et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One. 2008;3(8):e3088.CrossRefPubMedPubMedCentral
39.
40.
41.
Frappart PO, Lee Y, Russell HR, Chalhoub N, Wang YD, Orii KE, et al. Recurrent genomic alterations characterize medulloblastoma arising from DNA double-strand break repair deficiency. Proc Natl Acad Sci U S A. 2009;106(6):1880–5.CrossRefPubMedPubMedCentral
42.
Mille F, Tamayo-Orrego L, Levesque M, Remke M, Korshunov A, Cardin J, et al. The Shh receptor Boc promotes progression of early medulloblastoma to advanced tumors. Dev Cell. 2014;31(1):34–47.CrossRefPubMed
43.
44.
45.
Hu P, Yu L, Zhang M, Zheng L, Zhao Y, Fu Q, et al. Molecular cloning and mapping of the brain-abundant B1gamma subunit of protein phosphatase 2A, PPP2R2C, to human chromosome 4p16. Genomics. 2000;67(1):83–6.CrossRefPubMed
46.
Cundell MJ, Hutter LH, Nunes Bastos R, Poser E, Holder J, Mohammed S, et al. A PP2A-B55 recognition signal controls substrate dephosphorylation kinetics during mitotic exit. J Cell Biol. 2016;214(5):539–54.CrossRefPubMedPubMedCentral
47.
48.
Ruvolo PP. The broken "off" switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillance. BBA Clin. 2016;6:87–99.CrossRefPubMedPubMedCentral
49.
Sablina AA, Hahn WC. The role of PP2A A subunits in tumor suppression. Cell Adhes Migr. 2007;1(3):140–1.CrossRef
50.
51.
Kaur A, Westermarck J. Regulation of protein phosphatase 2A (PP2A) tumor suppressor function by PME-1. Biochem Soc Trans. 2016;44(6):1683–93.CrossRefPubMed
52.
Devilder MC, Cadoret E, Cherel M, Moreau I, Rondeau G, Bezieau S, et al. cDNA cloning, gene characterization and 13q14.3 chromosomal assignment of CHC1-L, a chromosome condensation regulator-like guanine nucleotide exchange factor. Genomics. 1998;54(1):99–106.CrossRefPubMed
53.
Latil A, Morant P, Fournier G, Mangin P, Berthon P, Cussenot O. CHC1-L, a candidate gene for prostate carcinogenesis at 13q14.2, is frequently affected by loss of heterozygosity and underexpressed in human prostate cancer. Int J Cancer. 2002;99(5):689–96.CrossRefPubMed
54.
Latil A, Chene L, Mangin P, Fournier G, Berthon P, Cussenot O. Extensive analysis of the 13q14 region in human prostate tumors: DNA analysis and quantitative expression of genes lying in the interval of deletion. Prostate. 2003;57(1):39–50.CrossRefPubMed
55.
Ross-Adams H, Lamb AD, Dunning MJ, Halim S, Lindberg J, Massie CM, et al. Integration of copy number and transcriptomics provides risk stratification in prostate cancer: a discovery and validation cohort study. EBioMedicine. 2015;2(9):1133–44.CrossRefPubMedPubMedCentral
56.
Maezawa S, Hayano T, Koiwai K, Fukushima R, Kouda K, Kubota T, et al. Bood POZ containing gene type 2 is a human counterpart of yeast Btb3p and promotes the degradation of terminal deoxynucleotidyltransferase. Genes Cells. 2008;13(5):439–57.CrossRefPubMed
57.
Janssens V, Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J. 2001;353(Pt 3):417–39.CrossRefPubMedPubMedCentral
58.
Pham TT, Angus SP, Johnson GL. MAP3K1: genomic alterations in cancer and function in promoting cell survival or apoptosis. Genes Cancer. 2013;4(11–12):419–26.CrossRefPubMedPubMedCentral
59.
Junttila MR, Li SP, Westermarck J. Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J. 2008;22(4):954–65.CrossRefPubMed
60.
Pearson CG, Osborn DP, Giddings TH Jr, Beales PL, Winey M. Basal body stability and ciliogenesis requires the conserved component Poc1. J Cell Biol. 2009;187(6):905–20.CrossRefPubMedPubMedCentral
61.
Huang S, Zhang Z, Zhang C, Lv X, Zheng X, Chen Z, et al. Activation of Smurf E3 ligase promoted by smoothened regulates hedgehog signaling through targeting patched turnover. PLoS Biol. 2013;11(11):e1001721.CrossRefPubMedPubMedCentral
62.
Farooqi AA, Waseem MS, Riaz AM, Bhatti S. SMURF and NEDD4: sharp shooters monitor the gate keepers and ion traffic controllers of lead astray cell. J Membr Biol. 2011;244(1):1–8.CrossRefPubMed
63.
Cui Y, He S, Xing C, Lu K, Wang J, Xing G, et al. SCFFBXL(1)(5) regulates BMP signalling by directing the degradation of HECT-type ubiquitin ligase Smurf1. EMBO J. 2011;30(13):2675–89.CrossRefPubMedPubMedCentral
64.
Malatesta M, Steinhauer C, Mohammad F, Pandey DP, Squatrito M, Helin K. Histone acetyltransferase PCAF is required for hedgehog-Gli-dependent transcription and cancer cell proliferation. Cancer Res. 2013;73(20):6323–33.CrossRefPubMed
65.
Zuhlke KA, Johnson AM, Tomlins SA, Palanisamy N, Carpten JD, Lange EM, et al. Identification of a novel germline SPOP mutation in a family with hereditary prostate cancer. Prostate. 2014;74(9):983–90.CrossRefPubMedPubMedCentral
66.
67.
Wen X, Lai CK, Evangelista M, Hongo JA, de Sauvage FJ, Scales SJ. Kinetics of hedgehog-dependent full-length Gli3 accumulation in primary cilia and subsequent degradation. Mol Cell Biol. 2010;30(8):1910–22.CrossRefPubMedPubMedCentral
68.
Zhang Q, Shi Q, Chen Y, Yue T, Li S, Wang B, et al. Multiple Ser/Thr-rich degrons mediate the degradation of ci/Gli by the Cul3-HIB/SPOP E3 ubiquitin ligase. Proc Natl Acad Sci U S A. 2009;106(50):21191–6.CrossRefPubMedPubMedCentral
69.
Gan W, Dai X, Lunardi A, Li Z, Inuzuka H, Liu P, et al. SPOP promotes ubiquitination and degradation of the ERG oncoprotein to suppress prostate cancer progression. Mol Cell. 2015;59(6):917–30.CrossRefPubMedPubMedCentral
70.
De Smaele E, Di Marcotullio L, Moretti M, Pelloni M, Occhione MA, Infante P, et al. Identification and characterization of KCASH2 and KCASH3, 2 novel Cullin3 adaptors suppressing histone deacetylase and hedgehog activity in medulloblastoma. Neoplasia. 2011;13(4):374–85.CrossRefPubMedPubMedCentral
71.
Canettieri G, Di Marcotullio L, Greco A, Coni S, Antonucci L, Infante P, et al. Histone deacetylase and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates hedgehog signalling through Gli acetylation. Nat Cell Biol. 2010;12(2):132–42.CrossRefPubMed
72.
Gulino A, Di Marcotullio L, Canettieri G, De Smaele E, Screpanti I. Hedgehog/Gli control by ubiquitination/acetylation interplay. Vitam Horm. 2012;88:211–27.CrossRefPubMed
73.
Canettieri G, Di Marcotullio L, Coni S, Greco A, Gulino A. Turning off the switch in medulloblastoma: the inhibitory acetylation of an oncogene. Cell Cycle. 2010;9(11):2047–8.CrossRefPubMed
74.
Korshunov A, Remke M, Kool M, Hielscher T, Northcott PA, Williamson D, et al. Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. Acta Neuropathol. 2012;123(4):515–27.CrossRefPubMed
75.
Ciechanover A, DiGiuseppe JA, Schwartz AL, Brodeur GM. Degradation of MYCN oncoprotein by the ubiquitin system. Prog Clin Biol Res. 1991;366:37–43.PubMed
76.
Otto T, Horn S, Brockmann M, Eilers U, Schuttrumpf L, Popov N, et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell. 2009;15(1):67–78.CrossRefPubMed
77.
Zhao X, Heng JI, Guardavaccaro D, Jiang R, Pagano M, Guillemot F, et al. The HECT-domain ubiquitin ligase Huwe1 controls neural differentiation and proliferation by destabilizing the N-Myc oncoprotein. Nat Cell Biol. 2008;10(6):643–53.CrossRefPubMedPubMedCentral
78.
King B, Boccalatte F, Moran-Crusio K, Wolf E, Wang J, Kayembe C, et al. The ubiquitin ligase Huwe1 regulates the maintenance and lymphoid commitment of hematopoietic stem cells. Nat Immunol. 2016;17(11):1312–21.CrossRefPubMedPubMedCentral
79.
Faisal A, Vaughan L, Bavetsias V, Sun C, Atrash B, Avery S, et al. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo. Mol Cancer Ther. 2011;10(11):2115–23.CrossRefPubMedPubMedCentral
80.
Tavana O, Li D, Dai C, Lopez G, Banerjee D, Kon N, et al. HAUSP deubiquitinates and stabilizes N-Myc in neuroblastoma. Nat Med. 2016;22(10):1180–6.CrossRefPubMedPubMedCentral
81.
82.
Poschl J, Bartels M, Ohli J, Bianchi E, Kuteykin-Teplyakov K, Grammel D, et al. Wnt/beta-catenin signaling inhibits the Shh pathway and impairs tumor growth in Shh-dependent medulloblastoma. Acta Neuropathol. 2014;127(4):605–7.CrossRefPubMed
83.
Blaess S, Stephen D, Joyner AL. Gli3 coordinates three-dimensional patterning and growth of the tectum and cerebellum by integrating Shh and Fgf8 signaling. Development. 2008;135(12):2093–103.CrossRefPubMed
84.
Schweiger S, Dorn S, Fuchs M, Kohler A, Matthes F, Muller EC, et al. The E3 ubiquitin ligase MID1 catalyzes ubiquitination and cleavage of Fu. J Biol Chem. 2014;289(46):31805–17.CrossRefPubMedPubMedCentral
85.
Du H, Huang Y, Zaghlula M, Walters E, Cox TC, Massiah MA. The MID1 E3 ligase catalyzes the polyubiquitination of Alpha4 (alpha4), a regulatory subunit of protein phosphatase 2A (PP2A): novel insights into MID1-mediated regulation of PP2A. J Biol Chem. 2013;288(29):21341–50.CrossRefPubMedPubMedCentral
86.
Lee EY, Ji H, Ouyang Z, Zhou B, Ma W, Vokes SA, et al. Hedgehog pathway-regulated gene networks in cerebellum development and tumorigenesis. Proc Natl Acad Sci U S A. 2010;107(21):9736–41.CrossRefPubMedPubMedCentral
87.
Vuong TA, Leem YE, Kim BG, Cho H, Lee SJ, Bae GU, et al. A sonic hedgehog coreceptor, BOC regulates neuronal differentiation and neurite outgrowth via interaction with ABL and JNK activation. Cell Signal. 2017;30:30–40.CrossRefPubMed
88.
Shahi MH, Afzal M, Sinha S, Eberhart CG, Rey JA, Fan X, et al. Human hedgehog interacting protein expression and promoter methylation in medulloblastoma cell lines and primary tumor samples. J Neuro-Oncol. 2011;103(2):287–96.CrossRef
89.
Tan J, Lee PL, Li Z, Jiang X, Lim YC, Hooi SC, et al. B55beta-associated PP2A complex controls PDK1-directed myc signaling and modulates rapamycin sensitivity in colorectal cancer. Cancer Cell. 2010;18(5):459–71.CrossRefPubMed
90.
Tan Y, Sun D, Jiang W, Klotz-Noack K, Vashisht AA, Wohlschlegel J, et al. PP2A-B55beta antagonizes cyclin E1 proteolysis and promotes its dysregulation in cancer. Cancer Res. 2014;74(7):2006–14.CrossRefPubMedPubMedCentral
91.
Oberg EA, Nifoussi SK, Gingras AC, Strack S. Selective proteasomal degradation of the B’beta subunit of protein phosphatase 2A by the E3 ubiquitin ligase adaptor Kelch-like 15. J Biol Chem. 2012;287(52):43378–89.CrossRefPubMedPubMedCentral
92.
De Simone A, Gonczy P. Computer simulations reveal mechanisms that organize nuclear dynein forces to separate centrosomes. Mol Biol Cell. 2017;28(23):3165–70.CrossRefPubMedPubMedCentral
93.
Mahale SP, Sharma A, Mylavarapu SV. Dynein light intermediate chain 2 facilitates the metaphase to anaphase transition by inactivating the spindle assembly checkpoint. PLoS One. 2016;11(7):e0159646.CrossRefPubMedPubMedCentral
94.
Qiu X, Huang Y, Zhou Y, Zheng F. Aberrant methylation of TRIM58 in hepatocellular carcinoma and its potential clinical implication. Oncol Rep. 2016;36(2):811–8.CrossRefPubMed
95.
Kajiura K, Masuda K, Naruto T, Kohmoto T, Watabnabe M, Tsuboi M, et al. Frequent silencing of the candidate tumor suppressor TRIM58 by promoter methylation in early-stage lung adenocarcinoma. Oncotarget. 2017;8(2):2890–905.CrossRefPubMed
96.
Zhang W, Mi J, Li N, Sui L, Wan T, Zhang J, et al. Identification and characterization of DPZF, a novel human BTB/POZ zinc finger protein sharing homology to BCL-6. Biochem Biophys Res Commun. 2001;282(4):1067–73.CrossRefPubMed
97.
Tonchev AB, Tuoc TC, Rosenthal EH, Studer M, Stoykova A. Zbtb20 modulates the sequential generation of neuronal layers in developing cortex. Mol Brain. 2016;9(1):65.CrossRefPubMedPubMedCentral
98.
Groisman R, Kuraoka I, Chevallier O, Gaye N, Magnaldo T, Tanaka K, et al. CSA-dependent degradation of CSB by the ubiquitin-proteasome pathway establishes a link between complementation factors of the Cockayne syndrome. Genes Dev. 2006;20(11):1429–34.CrossRefPubMedPubMedCentral
99.
Felsher DW. MYC inactivation elicits oncogene addiction through both tumor cell-intrinsic and host-dependent mechanisms. Genes Cancer. 2010;1(6):597–604.CrossRefPubMedPubMedCentral
100.
Suryo Rahmanto A, Savov V, Brunner A, Bolin S, Weishaupt H, Malyukova A, et al. FBW7 suppression leads to SOX9 stabilization and increased malignancy in medulloblastoma. EMBO J. 2016;35(20):2192–212.CrossRefPubMedPubMedCentral
101.
Kim SY, Herbst A, Tworkowski KA, Salghetti SE, Tansey WP. Skp2 regulates Myc protein stability and activity. Mol Cell. 2003;11(5):1177–88.CrossRefPubMed
102.
von der Lehr N, Johansson S, Wu S, Bahram F, Castell A, Cetinkaya C, et al. The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. Mol Cell. 2003;11(5):1189–200.CrossRefPubMed
103.
104.
Kalev P, Simicek M, Vazquez I, Munck S, Chen L, Soin T, et al. Loss of PPP2R2A inhibits homologous recombination DNA repair and predicts tumor sensitivity to PARP inhibition. Cancer Res. 2012;72(24):6414–24.CrossRefPubMed
105.
Zhang H, Cao D, Zhou L, Zhang Y, Guo X, Li H, et al. ZBTB20 is a sequence-specific transcriptional repressor of alpha-fetoprotein gene. Sci Rep. 2015;5:11979.CrossRefPubMedPubMedCentral
106.
Fedele V, Dai F, Masilamani AP, Heiland DH, Kling E, Gatjens-Sanchez AM, et al. Epigenetic regulation of ZBTB18 promotes glioblastoma progression. Mol Cancer Res. 2017;15(8):998–1011.CrossRefPubMedPubMedCentral
107.
Link LA, Howley BV, Hussey GS, Howe PH. PCBP1/HNRNP E1 protects chromosomal integrity by translational regulation of CDC27. Mol Cancer Res. 2016;14(7):634–46.CrossRefPubMedPubMedCentral
108.
Stewart S, Fang G. Anaphase-promoting complex/cyclosome controls the stability of TPX2 during mitotic exit. Mol Cell Biol. 2005;25(23):10516–27.CrossRefPubMedPubMedCentral
109.
110.
Manic G, Corradi F, Sistigu A, Siteni S, Vitale I. Molecular regulation of the spindle assembly checkpoint by kinases and phosphatases. Int Rev Cell Mol Biol. 2017;328:105–61.CrossRefPubMed
111.
Sansregret L, Patterson JO, Dewhurst S, Lopez-Garcia C, Koch A, McGranahan N, et al. APC/C dysfunction limits excessive cancer chromosomal instability. Cancer Discov. 2017;7(2):218–33.CrossRefPubMedPubMedCentral
112.
113.
Hagting A, Den Elzen N, Vodermaier HC, Waizenegger IC, Peters JM, Pines J. Human securin proteolysis is controlled by the spindle checkpoint and reveals when the APC/C switches from activation by Cdc20 to Cdh1. J Cell Biol. 2002;157(7):1125–37.CrossRefPubMedPubMedCentral
114.
115.
Hein JB, Hertz EPT, Garvanska DH, Kruse T, Nilsson J. Distinct kinetics of serine and threonine dephosphorylation are essential for mitosis. Nat Cell Biol. 2017;19(12):1433–40.CrossRefPubMed
116.
Manchado E, Guillamot M, de Carcer G, Eguren M, Trickey M, Garcia-Higuera I, et al. Targeting mitotic exit leads to tumor regression in vivo: modulation by Cdk1, Mastl, and the PP2A/B55alpha,delta phosphatase. Cancer Cell. 2010;18(6):641–54.CrossRefPubMed
117.
Densham RM, Garvin AJ, Stone HR, Strachan J, Baldock RA, Daza-Martin M, et al. Human BRCA1-BARD1 ubiquitin ligase activity counteracts chromatin barriers to DNA resection. Nat Struct Mol Biol. 2016;23(7):647–55.CrossRefPubMedPubMedCentral
118.
Hao Z, Zhang H, Cowell J. Ubiquitin-conjugating enzyme UBE2C: molecular biology, role in tumorigenesis, and potential as a biomarker. Tumour Biol. 2012;33(3):723–30.CrossRefPubMed
119.
Alshalalfa M, Schliekelman M, Shin H, Erho N, Davicioni E. Evolving transcriptomic fingerprint based on genome-wide data as prognostic tools in prostate cancer. Biol Cell. 2015;107(7):232–44.CrossRefPubMedPubMedCentral
120.
Liu Z, Yuan F, Ren J, Cao J, Zhou Y, Yang Q, et al. GPS-ARM: computational analysis of the APC/C recognition motif by predicting D-boxes and KEN-boxes. PLoS One. 2012;7(3):e34370.CrossRefPubMedPubMedCentral
121.
122.
Li W, Bengtson MH, Ulbrich A, Matsuda A, Reddy VA, Orth A, et al. Genome-wide and functional annotation of human E3 ubiquitin ligases identifies MULAN, a mitochondrial E3 that regulates the organelle’s dynamics and signaling. PLoS One. 2008;3(1):e1487.CrossRefPubMedPubMedCentral
123.
Lehmann G, Udasin RG, Ciechanover A. On the linkage between the ubiquitin-proteasome system and the mitochondria. Biochem Biophys Res Commun. 2016;473(1):80–6.CrossRefPubMed
124.
Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H, et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol. 2011;29(11):1424–30.CrossRefPubMed
125.
Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol. 2011;29(11):1408–14.CrossRefPubMed
126.
Remke M, Hielscher T, Northcott PA, Witt H, Ryzhova M, Wittmann A, et al. Adult medulloblastoma comprises three major molecular variants. J Clin Oncol. 2011;29(19):2717–23.CrossRefPubMed
127.
128.
Mochida S, Ikeo S, Gannon J, Hunt T. Regulated activity of PP2A-B55 delta is crucial for controlling entry into and exit from mitosis in Xenopus egg extracts. EMBO J. 2009;28(18):2777–85.CrossRefPubMedPubMedCentral
129.
Seshacharyulu P, Pandey P, Datta K, Batra SK. Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer. Cancer Lett. 2013;335(1):9–18.CrossRefPubMedPubMedCentral
130.
Nanahoshi M, Tsujishita Y, Tokunaga C, Inui S, Sakaguchi N, Hara K, et al. Alpha4 protein as a common regulator of type 2A-related serine/threonine protein phosphatases. FEBS Lett. 1999;446(1):108–12.CrossRefPubMed
131.
Metadaten
Titel
Differential Expression of Genes for Ubiquitin Ligases in Medulloblastoma Subtypes
verfasst von
Jerry Vriend
Robert B. Tate
Publikationsdatum
01.06.2019
Verlag
Springer US
Erschienen in
The Cerebellum / Ausgabe 3/2019
Print ISSN: 1473-4222
Elektronische ISSN: 1473-4230
DOI
https://doi.org/10.1007/s12311-019-1009-y

Weitere Artikel der Ausgabe 3/2019

Neocerebellar Crus I Abnormalities Associated with a Speech and Language Disorder Due to a Mutation in FOXP2

  • Open Access
  • Original Paper

The Cerebellar Thalamus

  • Review

Human Brain Region-Specific Alternative Splicing of TRPC3, the Type 3 Canonical Transient Receptor Potential Non-Selective Cation Channel

  • Original Paper

Fall Risk in Relation to Individual Physical Activity Exposure in Patients with Different Neurodegenerative Diseases: a Pilot Study

  • Original Paper

Age-Dependent White Matter Characteristics of the Cerebellar Peduncles from Infancy Through Adolescence

  • Original Paper

Neural Scaffolding as the Foundation for Stable Performance of Aging Cerebellum

  • Original Paper

Kompaktes Leitlinien-Wissen Neurologie (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Stumme Schlaganfälle − ein häufiger Nebenbefund im Kopf-CT?

In 4% der in der Notfallambulanz initiierten zerebralen Bildgebung sind „alte“ Schlaganfälle zu erkennen. Gar nicht so selten handelt es sich laut einer aktuellen Studie dabei um unbemerkte Insulte. Bietet sich hier womöglich die Chance auf ein effektives opportunistisches Screening?

CGRP-Antikörper auch bei älteren Migränekranken sicher

Beginnen ältere Migränekranke eine Prophylaxe mit CGRP-Antikörpern, kommt es anschließend nicht häufiger zu kardiovaskulären Problemen als unter einer Prophylaxe mit Botulinumtoxin. Darauf deutet eine US-Analyse von Medicare-Versicherten.

Frühwarnzeichen für multiple Sklerose bei Kindern und Jugendlichen

Ein Forschungsteam aus Deutschland und Kanada hat eine Reihe metabolischer, okulärer, muskuloskelettaler, gastrointestinaler und kardiovaskulärer Symptome identifiziert, die bei Kindern und Jugendlichen der Diagnose einer multiplen Sklerose (MS) vorausgehen können.

Migräne verstehen und psychotherapeutisch behandeln

Das Wissen über die Mechanismen, die im Gehirn bei einer Migräneattacke ablaufen, und mögliche Auslöser wird immer breiter. Der psychologische Psychotherapeut Dr. Dipl.-Psych. Timo Klan fasst den aktuellen Erkenntnisstand zusammen. Und er gibt Tipps für eine differenzierte, individuelle Diagnostik auch von Begleiterkrankungen und beschreibt erfolgreiche psychotherapeutische Interventionen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise